# 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

> **NCT05239182** · PHASE2 · TERMINATED · sponsor: **Anwaar Saeed** · enrollment: 7 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** 9-ING-41
- **DRUG:** Retifanlimab
- **DRUG:** Gemcitabine
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT05239182
- **Lead sponsor:** Anwaar Saeed
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-26
- **Primary completion:** 2022-12-20
- **Final completion:** 2024-02-04
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Backbone chemo regimen of gemzar/abraxane no longer most favorable treatment for pancreatic cancer patients.
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05239182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05239182, "9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05239182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*